The available pool of potential blood donors continues to decrease. There are blood component losses all along the chain of production from the recruitment of the donor, attendance and bleeding of the donor, production process, storage of the inventory in the blood center, storage in the hospital or laboratory, selection, and transfusion of the recipient. There is a requirement and potential to improve product availability by better recruitment strategies, production methods, inventory management, and recipient selection. All of these areas of transfusion medicine have been investigated, and some data and options for improving donor/donation utilization are available in the literature. There are also some developing strategies that have the potential to have a positive influence on the availability of blood components. They include the use of blood components that have often been regarded as expensive. Further studies are required to determine if products such as leukoreduced red cells and platelets, unrefrigerated or fresh whole blood, and some recombinant products can conserve large numbers of other components or reduce hospital costs.

中文翻译：

---

新鲜血液产品的制造、发行和使用：收益递减链？


可用的潜在献血者库继续减少。从献血者的招募、献血者的出勤和采血、生产过程、血液中心库存的储存、医院或实验室的储存、血液成分的选择和输血，整个生产链都存在血液成分的损失。接受者。通过更好的招聘策略、生产方法、库存管理和接收者选择来提高产品可用性是有必要和潜力的。输血医学的所有这些领域都已被研究，并且文献中提供了一些用于改善捐赠者/捐赠利用率的数据和选项。还有一些开发策略有可能对血液成分的可用性产生积极影响。其中包括使用通常被认为昂贵的血液成分。需要进一步研究以确定去白细胞红细胞和血小板、非冷藏或新鲜全血以及一些重组产品等产品是否可以节省大量其他成分或降低医院费用。